Merck has reached an agreement that will let other drug makers produce its COVID-19 pill, though many countries are excluded from the pact. Merck and the United Nations-backed Medicines Patent Pool announced the agreement, saying it would help broaden access to the treatment in 105 low- and middle-income countries. The pool will be allowed to…
Merck to Let Other Drug Companies Make Its COVID-19 Pill Under New Agreement
US Set to Pay $712 Per Patient for Merck’s COVID-19 Pill
Merck is set to get $712 per treatment course for its COVID-19 pill from the U.S. government—even as it costs a fraction of that to produce, and is reportedly on track for a price of $12 in India. The gap between production costs and the price for molnupiravir is gigantic and emblematic of a problem…
Merck Shares Soar on COVID-19 Pill Trial Results, Vaccine Stocks Dip
Shares of Merck & Co surged on positive clinical trial results of its experimental antiviral COVID-19 pill while high-flying stocks of vaccine companies and makers of other coronavirus therapies were bruised. Merck shares jumped as much as 12.3 percent and hit their highest level since February 2020 after data showed the company’s pill molnupiravir could halve…
US News
RSS Error: A feed could not be found at `https://www.theepochtimes.com/c-us/feed`; the status code is `200` and content-type is `text/html; charset=utf-8`